The trial is a Phase II, open-label trial in healthy subjects aged 18 to 60 years to support the immunogenicity data from previous clinical studies. Objectives: * To describe the immune response 21 days after each vaccination. * To describe the safety profiles following each vaccination.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
100
0.5 mL, Intramuscular
Unnamed facility
Adelaide, Australia
Unnamed facility
Queensland, Australia
To provide information concerning the immunogenicity of A/H5N1 inactivated, split-virion influenza virus vaccine
Time frame: Day 42 post-vaccination 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.